Nasdaq

Medtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System

ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...
BioWorld

Medtronic’s next-gen Interstim X system wins FDA nod

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
BioWorld

FDA greenlights Interstim Micro and Surescan MRI leads for bladder and bowel control

Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new ...
Nasdaq

Medtronic Initiates Post-Market ELITE Study for SNM Therapy

Medtronic plc MDT recently commenced the enrolment for a prospective, multicenter, global, post-market study of its InterStim Micro neurostimulator — Evaluation of InterStim Micro System Performance ...
Business Insider

Medtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System

ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...